Iran’s Scientific Achievement in the Heart of Global Innovation: SVIIF 2025 Gold Medal
Iranian researchers and inventors won the gold medal and special award at the prestigious Silicon Valley International Invention Festival (SVIIF) 2025 in the United States in the field of medicine and pharmaceuticals. Their groundbreaking invention, titled: “Nanoformulation Containing Exosome-Derived Monoclonal Antibody and Drug Carrier Ligand Against Transferrin Receptor for Targeted Drug Delivery to Glioblastoma Brain Cancer Cells”was honored during the competition, held on August 8–10, 2025 (17–19 Mordad 1404) at the Santa Clara Convention Center in California’s Silicon Valley.
The Inventor Team:Dr. Reza Mosaddeghi Heris: Project leader; inventor and researcher in innovative therapies for neurodegenerative diseases and central nervous system cancers; MD from Tabriz University of Medical Sciences; senior researcher at Valiasr Hospital’s Clinical Research Development Unit and the Neuroscience Research Center of Tabriz University of Medical Sciences. Author of over 40 research articles in top international journals including The Lancet and The Lancet Neurology; writer of more than 10 books on neuroscience and AI; collaborator on Global Burden of Disease projects with IHME at the University of Washington, USA; editorial board member of Inflammopharmacology (Switzerland).
Dr. Hamed Aghazadeh: Inventor and researcher in cancer, stem cells, drug delivery systems and formulations; microbiologist; MSc in Pharmaceutical Engineering (M.Pharm.Eng) from the University of Tehran; Doctor of Pharmacy (Pharm.D.) candidate.
Dr. Tahereh Sangchooli: Inventor and researcher in cancer and drug delivery systems; chemist; MSc in Pharmaceutical Engineering; Pharm.D. candidate. Holder of several gold medals at international invention competitions in the USA, Turkey, and Dubai University; author of multiple international patents, articles, and books in pharmacy, medicine, and oncology; CEO of Oxin Darou Novavar Company.Dr. Reyhaneh Nasr Azadani: Inventor and researcher in cancer, tissue engineering, and regenerative medicine; MSc in Biomedical Engineering (Bioelectric) and MSc in Biomaterials Engineering from Isfahan University of Medical Sciences; PhD candidate in Tissue Engineering. Winner of top innovation awards in Nuremberg (Germany), special award and gold medal at the 50th International Exhibition of Inventions Geneva (Switzerland 2025), and gold medals in Turkey and Saudi Arabia. Author of numerous international publications, patents, and books in medicine, cancer, and regenerative medicine.Dr. Sahar Hefzollesan: Inventor and researcher in biomaterials, tissue engineering, restorative dentistry, and nanocomposites; DDS and PhD in Dental Materials from Azerbaijan Medical University; prosthodontist and implant specialist; Head of Dentistry Department at Medera Specialty and Subspecialty Hospital in Azerbaijan.
Dr. Fatemeh Kabiri: Inventor and researcher in drug delivery systems, formulations, nanodrugs, and nucleotide-based medicines; Pharm.D. from Tehran University of Medical Sciences; PhD candidate in Pharmaceutics at Tehran University of Medical Sciences; member of Iran’s National Elite Foundation; special award and gold medal winner at the 50th International Exhibition of Inventions Geneva (2025); active in international projects, industry, and specialized pharmacies.Dr. Sahra Hefzollesan: Inventor and researcher in biomaterials, tissue engineering, restorative dentistry, and nanocomposites; DDS from Karadeniz Technical University, Turkey.Dr. Somayeh Pour Esmaeil: Inventor and researcher in pathology, anatomy, autoimmune diseases (MS), and physiotherapy; MD candidate at Dokuz Eylul University (Turkey); MSc in Physical Education from Islamic Azad University of Tabriz; BSc in Physiotherapy from Giresun University (Turkey). Inventor of novel therapeutic methods in physiotherapy and treatment of anatomical abnormalities.
Dr. Kimia Bagheri: Inventor and researcher in brain tumors, malignancies, and central nervous system cancers; MD from Babol University of Medical Sciences; MPH from Shiraz University of Medical Sciences. Author of numerous international scientific publications and books in neuroscience; collaborator on international projects, including with Keck Medicine of USC in California, USA, in brain tumor and AI research; health policy researcher, particularly on irrational drug use in Iran; member of the World Inventors Organization; gold medal winner at the 2025 Geneva International Inventions competition.Dr. Amirhossein Shahbaz: Inventor and researcher in cancer and tissue engineering, with expertise in drug delivery, bone regeneration, bone implants, and innovative health solutions; PhD in Biomaterials Engineering and MSc in Biomaterials Engineering from Islamic Azad University of Karaj; DBA Pharma student at Tehran University of Medical Sciences; author of several international research papers and patents.
Award & RecognitionThis team’s pioneering project, “Nanoformulation Containing Exosome-Derived Monoclonal Antibody and Drug Carrier Ligand Against Transferrin Receptor for Targeted Drug Delivery to Glioblastoma Brain Cancer Cells”, won the gold medal and special award at SVIIF 2025 in the United States.Mr. Hamed Aghazadeh, CEO of Novian Gene Biotech Research Company and one of the inventors of the project, told our correspondent:“The Silicon Valley International Invention Festival (SVIIF 2025) was held on August 8–10, 2025 (17–19 Mordad 1404), organized by the International Federation of Inventors’ Associations (IFIA), with the support of the World Intellectual Property Organization (WIPO) and the United Inventors Association of the USA (UIA), at the Santa Clara Convention Center, Silicon Valley.”He added: “The competition featured inventors from leading U.S. universities and research institutes, along with innovators from over 25 countries across five continents—including the USA, Canada, UAE, Hong Kong, China, Croatia, Czech Republic, Poland, Germany, South Korea, Thailand, Vietnam, Tajikistan, Spain, and more—presenting over 200 inventions. This diverse participation highlighted the truly international spirit of the festival and the meeting point of East and West in the heart of Silicon Valley.”
He continued:“One of the highlights of this event was the strong presence of Iranian inventors. With more than 40 inventions and innovations presented by Iranian participants, our country played a significant role in the festival. Ultimately, several of our inventors won gold, silver, and bronze medals, as well as special international awards and certificates, further strengthening Iran’s position in global innovation.”Dr. Aghazadeh explained:“The judging process was conducted by an international multidisciplinary panel of professors, technologists, intellectual property experts, and industry leaders. This ensured accuracy, transparency, and fairness so that only the best inventions were recognized. Out of 1,200 participants from 25 countries worldwide, our team won the first place globally in the field of medicine and pharmaceuticals.”He emphasized:“Anyone with a prototype or even a final product can participate in this festival, seeking manufacturers, distributors, or investors who recognize the potential of their invention. The presented inventions spanned diverse fields, including medicine, pharmacy, engineering, technology, energy, environment, safety, and industry, offering practical solutions to improve daily life.”
On commercialization opportunities, he noted:Participation in the Silicon Valley trade exhibition is an effective way to showcase inventions, gain media attention, and connect with global businesses. It provides inventors direct access to investors and representatives of renowned companies for commercialization and funding.Dr. Aghazadeh further described the innovation:In this project, a nano-liposomal formulation was designed and developed, functionalized with exosome-derived monoclonal antibodies and specific drug-binding ligands, targeting the transferrin receptor (TfR) on brain capillaries. The main goal of this technology is to enhance the efficacy and reduce the side effects of cisplatin in glioblastoma treatmenta major challenge being the crossing of the blood–brain barrier.In short, this innovation integrates exosome-derived monoclonal antibodies and specific ligands into targeted nanoliposomal particles, leading to improved drug targeting, higher therapeutic efficacy, and reduced systemic toxicity in glioblastoma therapy. This technology not only demonstrates strong therapeutic potential but also industrial scalability and commercialization capacity, marking a milestone in targeted drug delivery to brain tumors.”#Dr_Reza_Mosaddeghi_Heris#Dr_Hamed_Aghazadeh#Dr_Tahereh_Sangchooli#Dr_Reyhaneh_Nasr_Azadani#Dr_Sahar_Hefzollesan#Dr_Fatemeh_Kabiri#Dr_Sahra_Hefzollesan#Dr_Somayeh_Pour_Esmaeil#Dr_Kimia_Bagheri#Dr_Amirhossein_Shahbaz#SVIIF_2025#Silicon_Valley
13:48 - 7 مهر 1404
595 بازدید
تازه ترین اخبار
- ایران، خونه منه
- حضرت آیت الله سید مجتبی خامنهای رهبر معظم انقلاب اسلامی پیامی به مناسبت گرامیداشت روز جمهوری اسلامی ایران و روز طبیعت صادر کردند.
- بندرترکمن؛ شهر بیدار در ۳۲ شب حماسه
- نماز استغاثه به امام زمان در میدان جمهوری اسلامی اصفهان
- برگزاری نماز استغاثه در پایان راهپیمایی شب سیودوم شهرستان بابل
- سیودومین شب حماسه ایلام
- قرائت نماز استغاثه به امام زمان در بهارستان
- قیام مردم اردستان در ایستگاه سی و دوم
- بهمئیها ولکن میدان نیستند
- فیلم| اقامه نماز استغاثه امام زمان (عج) در رشت